Three novel compounds, namely, phenoxan, phenalamide A 1 , and thiangazole, were found to suppress HIV-1 replication in cell cultures. The compounds were discovered by screening crude extracts from myxobacteria and were isolated from two strains of Polyangium sp. and a strain of Myxococcus stipitatus. Their structures have been elucidated. The cytotoxic concentrations for MT-4 cells were 6.6 JLM for phenoxan, 102JLM for phenalamide A lI and 4.7JLM for thiangazole. Phenoxan inhibited the HIV-1-dependent cell death at concentrations of as low as 6.6 nM. Phenalamide A 1 could prevent the HIV-1 infection of MT-4 cells even at concentrations of 1.02nM, and thiangazole at 4.7pM. In our assay thiangazole is at least 100 times more active than AZT. The compounds could not prevent syncythia formation induced by HIV-1. However, like HEPT (Baba et al., 1989; Miyasaka et al., 1989) and TIBO (Pauwels et al., 1990) derivatives they are highly specific since they could not interfere with HIV-2ben dependent MT-4 cell death. HIV-1 RT activity was inhibited by 50% by 376 JLM phenoxan, 386JLM phenalamid A 1 , or 263JLM thlanqazole, Since these concentrations are approximately 50000 times higher than their minimum concentrations active in cell cultures, RT-inhibition does not appear to be the major mechanism of HIV-inhibition of the new agents. . 'For correspondence. Tel. 0551 38510; Fax 0551 3851 228.
Introduction
The only licensed antiviral drug for the treatment of patients with AIDS and AIDS-related complex (ARC) is azidothymidine (3'-azido-Z' ,3' -dideoxythymidine, AZT, zidovudine). However, AZT must be administered for life, and it has severe toxic side effects (Richmann et aI., 1987) . Moreover, after prolonged AZT-treatment resistant HIV-variants develop (Larder et al., 1989a,b; Land et aI., 1990) . Thus, additional therapeutic compounds that either complement or substitute AZT are required urgently.
Gliding Gram-negative myxobacteria produce a large number of secondary metabolites, some of them with antibiotic properties (Reichenbach et al., 1988) . In a screening programme extracts of myxobacteria were analysed for their ability to inhibit HIV infection in a MT-4 cell culture assay. Phenoxan, phenalamide A 1 , and thiangazole were isolated and their antiviral effects were evaluated with respect to inhibition of HIV-1 reverse transcriptase (RD and syncytia formation.
Results
By screening for anti-HIV active compounds produced by myxobacteria three novel compounds, phenoxan, phenalamide A 1 , and thiangazole have been found ( Fig. 1) .These compounds were examined for anti-HIV-1 activity and cytotoxicity in the MT-4 cell culture assay. The anti-HIV-1 efficacies of these compounds were compared to that of AZT. In an attempt to elucidate their specificity, the compounds were further examined for inhibition of HIV-2 infection in MT-4 cells. To shed light on their mechanism of action, HIV-RT inhibition and interference with syncytia formation were determined.
Anti-HIV activity and cytotoxicity in MT-4 cell assay
The 3H-thymidine incorporation into MT-4 cell DNA in the presence or absence of HIV-1 was plotted against various concentrations of the compounds (Fig. 2) . Minimum toxic and maximum anti-HIV-1 concentrations of the compounds are summarized in Table 1 .
Phenoxan and thiangazole were not toxic for MT-4 cells at the highest examined concentrations of 6600nM and 4700nM, respectively. Phenalamide A 1 was toxic for MT-4 cells in concentrations above 102000 nM (fable 1, Table  2 ). The compounds were also examined for their toxicity towards the Iymphoblastoid cell lines H9, Jurkat, Molt-4 clone 8, Molt-3, and Raji (fable 2). The H9 cells turned out to be the most sensitive cell line. Phenoxan, phenalamide A 1 and thiangazole were toxic for H9 cells at concentrations of 6600 nM, 10200 nM, and 470 nM, respectively. Thus the compounds were at least 10 fold more toxic for H9 cells than for MT-4 cells. Thiangazole appears to be the most toxic compound among the three compounds examined.
added to co-cultures of Molt-4 clone 8 cells and persistently HIV-1111B-infected Molt-4 cells, multi-nucleated giant cells were observed even at the highest tested concentrations of 6.6 f.1M phenoxan, 10.2 f.1M phenalamide A 1 , and 4.7 f.1M thiangazole (data not shown). As shown in Table 1 , all three compounds deriving from myxobacteria were able to inhibit the HIV-1 RT activity. Thus, 376f.1M phenoxan, 386f.1M phenalamide A 1 , and 252 f.1M thiangazole inhibited the RT-activity to 50%.
RT-inhibition
Of phenoxan 6.6nM and of phenylamide A 1 1.02nM suppressed HIV-1-mediated cell death in the MT-4 cell assay, whereas thiangazole with an antiviral concentration of 4.7 pM was at least 10-100 fold more efficient. Therefore, thiangazole has the highest selectivity index (81) of 10 6 among the three newly isolated compounds and AZT (fable 1).
When the compounds were tested for HIV-2ben inhibition on MT-4 cells, none of them could prevent the HIV-2ben dependent MT-4 cell death (data not shown).
Syncytia assay
When different concentrations of the compounds were These concentrations are at least 7000 fold higher than those obtained with AZT-5'-triphosphate (Baba et al., 1989) .
Discussion
Phenoxan, phenalamide At, and thiangazole suppress HIV-111IB replication in vitro. Phenoxan and phenalamide At completely inhibited HIV-1111B-induced cytopathogeni-· city in MT-4 cells at concentrations as low as 6.6 nM and 1.02nM, respectively, whereas thiangazole was active against HIV-1 infection at concentrations down to 4.7pM.
Since the toxicity of a compound is critical for its potential use as a chemotherapeutic agent the toxicity of our compounds was evaluated not only with MT-4 cells but also with four additionallymphoblastoid cell lines. The cell-toxic concentrations of phenoxan, phenalamide At, and thiangazole were similar for all cell lines except for H9 cells Which were more sensitive.
It could be shown in beef heart submitochondrial particles, that phenoxan inhibits the reduction of cytochrome b when NADH is the electron donor, and that 50% of NADH oxidation is blocked by 5.8 nMphenoxan . Thus, phenoxan interferes with the electron transport in the eukaryotic respiratory chain. Nevertheless, the toxic concentration of phenoxan was more than 100 fold lower for different human Iymphoblastoid cell lines than for isolated submitochondrial particles.
Thiangazole appeared to be more toxic than phenoxan and phenalamide At. However, thiangazole had the highest selectivity index (SI), at least 100 times higher than AZT and R82150, the prototype TIBO-derivative, with Sis of 10 4 and 3 x 10 4 (Baba et aI., 1989) , respectively. Preliminary data showed that the three new compounds were able to inhibit the infection of MT-4 cells by HIV-1cc (kindly provided by Dr M. Popovic, NCI, Bethesda, MD, USA). Since the HIV-efficacy as well as the toxic dose of an agent depend on the HIV-specific antiviral assay system and the HIV-strain used, further tests with different HIV-1 and HIV-2 strains are in progress.
HIV-1 inhibitors from myxobacteria 191
In an attempt to elucidate the specificity of the new compounds, they were examined for inhibition of HIV-2 infection in the MT-4 assay. However, the compounds did not inhibit HIV-2ben infection in MT-4 cells. Obviously, the three myxobacterial compounds are able to discriminate between HIV-1 and HIV-2. A similar selective effect was shown for the HIV-1 RT-inhibitors HEPT (Baba et aI., 1989; Miyasaka et al. 1989 ) and TIBO derivatives (Pauwels et al., 1990) .
Phenoxan, phenalamide At, and thiangazole inhibit the HIV-1 RT. However these concentrations are at least 50000fold higher than those active in the MT-4 cell assay. Thus, their primary mechanism of action does not appear to be the inhibition of RT.
In a further attempt to elucidate the mode of action of the compounds they were tested for inhibition of syncytia formation induced by the interaction between the gp120 expressed on the surface of cells that have been infected with HIV-1, and CD4 receptor of non-infected CD4-positive cells. In contrast to various sulphated polysaccharides, which inhibit cell fusion by blocking virus adsorption to the cells (Nakashima et aI., 1987a,b; De Clercq, 1989) , none of our compounds could prevent the formation of giant cells in acutely HIV-1-infected CD4 positive Molt-4 cells. This suggests that they do not -affect early virus receptor interaction.
Our results illustrate that myxobacteria produce compounds that are highly active in HIV-1 suppression. The three new substances will be modified chemically to optimize their antiviral effect. Such compounds may be synergistic in combination with other HIV-inhibitors such asAZT.
Materials and Experimental procedures

Compounds
Phenoxan, phenalamide A" and thiangazole (Fig. 1) were isolated from strains of the myxobacteria Po/yangium sp, and Myxococcus stipitatus (Jansen et el., 1991 (Jansen et el., , 1992 Trowitzsch-Kienast et a/., 1992) . AZT was obtained from Wellcome (Burgwedel, Germany).
MT-4 cell assay
Phenoxan, phenalamide A" and thiangazole were examined for their anti HIV-1 and HIV-2 activity in the MT-4 cell assay . The Ills strain of HIV-1 (Popovic et el., 1984) was grown in Jurkat cells (Wendler et el., 1987) , whereas HIV-2ben (Schneider et a/., 1990) was propagated in Molt-4 cells. Jurkat, Molt-4 and MT-4 cells were grown in RPMI 1640 medium (Gibco, Karlsruhe, Germany) supplemented with 10% (vlv) heat-inactivated fetal bovine serum (FCS, Seromed, Berlin, Germany). During the cultivation in the MT-4 cell assay the cells were grown in RPMI 1640 medium with 25 mM HEPES (2-4(2-hydroxyethyl)-1-piperazinyl-ethansulphonate) and 10% FCS.
The MT-4 cell assay was performed in 96-well microtitre plates.
Serial dilutions of the compounds were incubated with 3 x 10 4
MT-4 cells per well, in the presence or absence of virus. The final virus concentration was 100 TCIDso of HIV-1 or HIV-2, respectively. Fresh medium was added to each well 3 days after infection. Four days after infection, 0.1 J.LCi of 3H-thymidine (Amersham, Oakville, Ontario) was added per well. After 20h the cellular DNA was harvested on glass fibre filters and the 3H-thymidine incorporated was determined in a scintillation counter using PPO, POPOP, and toluene as scintillator (Roth, Karlsruhe, Germany). The antiviral activities of the new compounds were compared to that of AZT.
Syncytia assay
To determine the inhibition of the HIV-1 induced cell fusion by phenoxan, phenalamide A 1 , and thiangazole a syncytia assay was performed (Tochikura et a/., 1988) . were incubated for 20 h at 37"C, and the cell fusion was detected by microscopy.
Reverse transcriptase inhibition assay
HIV-11I1B was harvested from infected Jurkat cells by centrifugation. The virus pellet was lysed in 10 mMTris-HCI pH 8.0 and 1% Triton X-100 and the virus purified in a 20:-70% sucrose density gradient in phosphate-buffered saline (PBS) pH 7.2. After centrifugation at 200000 x g for 15h at 4°C the reverse transcriptase (RT) activities of the fractions were measured. Fractions with the highest activity were collected and diluted with the same amount of ultrapure glycerol (v/v). When allquots of this HIV preparation were kept at -20°C the RT activity was stable for at least 3 months. The RT-assay was performed according to the procedure of . In the RT-inhibition assay 50J.L1 of reaction sample contained the compound to be tested in 50mM Tris-HCI I?H 7.8, 5mM DTT, 25mM Mg 2CI2, 30mM KCI, 6% Triton X-100, 1 [Lg Poly r C:Oligo dG, 9 [LM dGTP, 1 [LCi 32p-dGTP and lysed HIV-1. The specific activity of the viral RT was 1 nmol dGMP incorporation per mg protein during 45 min at 42°C. The RT reaction was stopped by the addition of 20 J.LI of 10% sodium dodecyl sulphate in water. The samples were transferred onto DEAE filters (Whatman, UK), washed with 5% Na2HP04, water, and ethanol and then dried. The radioactivity on the filters was measured in a scintillation counter after the addition of PPO, POPOP, and toluene. The 50% inhibitory concentration of the compound (IC so ) was determined graphically.
Toxicity
The cell toxicity of the compounds was determined for the human Iymphoblastoid cell lines MT-4 (Miyoshi et ei., 1981) , H9 (Popovic et el., 1984) , Jurkat (Schneider et el., 1977) , Molt-3 cells (Minowada et a/., 1972), Molt-4 clone 8 cells (Kikukawa et el., 1986) , and the EBV positive B cell line Raji (Pulvertaft, 1965) . Inhibition by phenoxan, phenalamide A 1 , and thiangazole was assessed in rnicrotitre plates with 3 x 10 4 cells per well. The cell growth was evaluated by measuring 3H-thymidine incorporation as described above.
